For patients harboring GBM with unmethylated O6 methylguanine DNA methyltransferase (MGMT) promoter, 2‐year survival rate is only 14% compared to 46% for those with methylated MGMT promoter6 and thus, MGMT promoter status is both prognostic and predictive of treatment response to TMZ chemotherapy. Here, MGMT is linked to glioblastoma.